Know Cancer

or
forgot password


N/A
18 Years
65 Years
Not Enrolling
Both
Multiple Myeloma

Thank you

Trial Information


First whole body FDG-PET scan and MRI before the start of the treatment. Second whole body
FDG-PET scan and MRI after the end of the treatment. On a basis of patient, comparison
between PET and MRI will be done tumoral site by site. Sensitivity, Specificity will be
estimated for both techniques. In case of discrepancy, another imaging method or biopsy (if
easy to perform) will be serve as standard of reference. Kappa coefficients and Mc Nemar
test will be performed to compare the two methods. FDG = fluorodeoxyglucose FLUCIS®
(Schering-CisBio® international)


Inclusion Criteria:



- Patients from 18 to 65 years old.

- De novo histologically proven multiple myeloma.

Exclusion Criteria:

- No history of another cancer or of HIV

- No history of renal failure

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Principal Investigator

Olivier Couturier, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Nantes University Hospital

Authority:

France: Ministry of Health

Study ID:

BRD/04/6-H

NCT ID:

NCT00200668

Start Date:

March 2005

Completion Date:

December 2006

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location